Care Management for the Effective Use of Opioids (CAMEO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01236521|
Recruitment Status : Completed
First Posted : November 8, 2010
Results First Posted : June 8, 2018
Last Update Posted : June 8, 2018
|Condition or disease||Intervention/treatment||Phase|
|Low Back Pain Pain||Drug: Pharmacological (PHARM) Behavioral: Behavioral treatment (BEH)||Not Applicable|
The general purpose of the CAre Management for the Effective use of Opioids (CAMEO) study is to develop, test, and implement novel treatments and care delivery models that address barriers to effective pain management and that can be practicably applied in VA primary care settings for chronic low back pain (CLBP). The CAMEO trial is a 2-arm randomized clinical trial to compare the effectiveness of pharmacological vs. behavioral approaches for CLBP.
The investigators' study sample will include 450 Veterans with moderate to severe CLBP despite long-term opioid therapy. Patients from five primary care clinics at the Roudebush VA Medical Center and two community based outpatient clinics will be recruited to participate in CAMEO and randomized to one of two treatment arms. The pharmacological arm will involve guideline-concordant opioid management coupled with algorithm-based co-analgesic treatment (PHARM). Patients in the behavioral arm (BEH) will receive pain self-management/coping skills training. The trial will last 12-months and all participants will undergo comprehensive outcome assessments at baseline, 3, 6, 9, and 12 months.
Study Aims: Among Veterans with chronic low back pain refractory to long-term opioid therapy
- To compare the interventions' (PHARM vs. BEH) effects on pain intensity and function at 6 months (primary end point) and 12 months (sustained effect)
To compare the interventions' effects (PHARM vs. BEH) on other relevant outcomes
- Patient global impression of change
- Health-related quality of life
- Opioid dose
- To compare the cost-effectiveness of the interventions
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||261 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Care Management for the Effective Use of Opioids (CAMEO)|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Experimental: Arm 1: Pharmacological (PHARM)
Subjects in the Pharmacological (PHARM) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
Drug: Pharmacological (PHARM)
During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.
The Patients in the PHARM arm will be asked to sign an opioid treatment agreement at enrollment.
Other Name: Co-analgesic algorithm
Experimental: Arm 2: Behavioral treatment (BEH)
Veterans randomized to behavioral treatment arm (BEH) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
Behavioral: Behavioral treatment (BEH)
There will be 8 sessions of pain self-management and coping skills.
Other Name: Pain self-management/coping skills treatment
- Brief Pain Inventory Total Score [ Time Frame: Baseline and 3, 6, 9, and 12 months ]The Brief Pain Inventory Total Score combines scores from the BPI Pain Intensity subscale and the BPI Pain Interference subscale. This scale provides a total score from 0 (no pain/no pain interference) to 10 (worst pain imaginable/completely interferes)
- Brief Pain Inventory Pain Intensity Score [ Time Frame: Baseline and 3, 6, 9, and 12 months ]The Brief Pain Inventory pain intensity score is scored from 0 (no pain) to 10 (worst pain imaginable).
- Brief Pain Inventory Pain Interference Scale Score [ Time Frame: Baseline and 3, 6, 9, and 12 months ]The Brief Pain Inventory Pain Interference Scale score assesses if pain interferes with 7 common activities. This scale is score 0 (no interference) to 10 (high interference). The 7-items are averaged to give a score.
- Pain Catastrophizing Scale [ Time Frame: baseline ]The Pain Catastrophizing Scale a 13-item scale that assesses catastrophizing - a pain belief that have been found to be strong predictor of poor treatment response. It is scored from 0 (no catastrophizing) to 52 (severe catastrophizing)
- Roland Morris Disability Scale [ Time Frame: Baseline ]The Roland Morris Disability Scale is a 24-item pain-specific measure of physical disability. It provides a score from 0 (no disability) to 24 (high disability)
- Patient Health Questionnaire-9 [ Time Frame: Baseline ]The Patient Health Questionnaire-9 is used to assess depression severity. It's 9-items that are scored from 0 (no depression) to 27 (severe depression)
- GAD-7 [ Time Frame: Baseline ]The GAD-7 is a measure of anxiety. The GAD-7 consists of 7 items that are scored from 0 (no anxiety) to 21 (severe anxiety)
- AUDIT-C [ Time Frame: Baseline ]The AUDIT-C is validated as an effective screening test and diagnostic tool for alcohol misuse in primary care samples. It is scored on 0 to 10 score with higher scores representing alcohol misuse
- Current Opioid Misuse Measure (COMM) [ Time Frame: baseline ]The COMM (Current Opioid Misuse Measure) is a 17-item instrument designed to monitor misuse and aberrant behaviors in patients prescribed opioids. The scale is scored from 0 (no evidence of opioid misuse or aberrant behaviors) to 64 (strong evidence for opioid misuse and aberrant behaviors)
- SF-36 General Health Perception [ Time Frame: baseline ]The SF-36 is a subscale that assesses the self-reported general health. It is scored on a 0 to 100 scale with higher scores representing greater perceived general health
- SF-36 Vitality Scale [ Time Frame: baseline ]The SF-36 vital score is a subscale that assesses participants' vitality/energy. It is scored on a 0 to 100 scale with higher scores representing greater vitality/energy.
- SF-36 Social Functioning Scale [ Time Frame: Baseline ]The SF-36 social functioning scale is a subscale that assesses the self-reported social functioning. It is scored on a 0 to 100 scale with higher scores representing better social functioning.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01236521
|United States, Indiana|
|Richard L. Roudebush VA Medical Center, Indianapolis, IN|
|Indianapolis, Indiana, United States, 46202-2884|
|Principal Investigator:||Matthew J. Bair, MD MS||Richard L. Roudebush VA Medical Center, Indianapolis, IN|